In the past, survival in Multiple Myeloma was in the range of 1 to 3 years. With the introduction of the novel drugs as the immunomodulators (IMiDs) and Proteosome inhibitors, survival has markedly increased and quality of life has improved. In this book, I have given an overview of the novel drugs and their use as first line therapy in multiple myeloma aiming for better prognosis, survival and quality of life.
| Вес: | 501 |